Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future
Interstitial lung diseases (ILD) are a spectrum of disorders often complicated by pulmonary hypertension (PH) in its course. The pathophysiologic mechanism of WHO group 3 PH is different to other forms of PH. The advent of PH is a harbinger for adverse events like mortality and morbidity, implying t...
Main Authors: | Ahmad Arslan, Jorden Smith, Muhammad Raheel Qureshi, Askin Uysal, Kapil K. Patel, Jose D. Herazo-Maya, Debabrata Bandyopadhyay |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-01-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1306032/full |
Similar Items
-
Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
by: Shelsey W. Johnson, et al.
Published: (2022-07-01) -
Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection
by: Raj Parikh, et al.
Published: (2022-10-01) -
INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
by: Nicholas S. Hill, et al.
Published: (2022-07-01) -
BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
by: Leslie A. Spikes, et al.
Published: (2022-04-01) -
PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis
by: Ning Zhao, et al.
Published: (2022-11-01)